PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid ...

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that it will present ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

Adding venetoclax to oral decitabine-cedazuridine improves responses in higher-risk MDS and CMML patients. Inqovi, an oral decitabine-cedazuridine combination, was FDA approved in 2020 for primary or ...

The prognostic impact of monocytosis in patients with myelodysplastic syndromes (MDS) is not well-studied and not been clearly defined. Patients with MDS and monocytosis had a shorter overall survival ...

Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of company's proprietary CyTAC™ and TicTAC™ platforms. Phase 1 trial of STX-0712 to ...

Safety findings from the study were comparable with those previously observed with IV decitabine. The most common treatment-emergent adverse events of thrombocytopenia, neutropenia and anemia were ...

Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study Newly diagnosed ...

FRANKFURT, Germany — A novel agent has shown promise in the treatment of chronic myelomonocytic leukemia (CMML), a rare, aggressive malignancy of myeloid cells with an inherent risk of transforming ...